Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.Kathleen N. Moore, Toon Van Gorp, Antoine Angelergues et al.|Journal of Clinical Oncology|2023Cited by 53
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.Nehal J. Lakhani, Kathleen N. Moore, David S. Miller et al.|Journal of Clinical Oncology|2020Cited by 37